BQR-695 is primarily investigated for its potential in cancer therapy, specifically as a dual inhibitor targeting key signaling pathways involved in tumor growth and survival. It modulates both the JAK/STAT and MAPK pathways, which are frequently dysregulated in various malignancies. This compound shows promise in preclinical studies for treating hematological cancers such as multiple myeloma and certain leukemias by inducing apoptosis and suppressing proliferation of cancer cells. Its ability to overcome resistance to conventional therapies makes it a candidate for combination treatment strategies. Research is ongoing to evaluate its efficacy and safety in advanced disease settings.